How to Establish Cell-Based Assays for Effective Antibody Development

Cell-Based Assays for Effective Antibody Development

Determining how a therapeutic antibody acts at the cellular level is critical to preclinical development. While biochemical assays play an essential role in early target validation and lead characterization, they only capture a fraction of the complexity of cell biology.

Engineered cell lines, primary cells, and 3D culturing systems, along with the cell-based assays they support, provide a more physiologically- and clinically-relevant context, delivering more predictive data on binding, signaling, and functional activity. As a result, robust cell-based systems are not a downstream consideration; they are foundational to antibody discovery and development.

Cell Lines Across the Antibody Discovery Workflow

Engineered cell lines and primary cells support multiple stages of antibody development. They can be used for immunization, ensuring that antibodies are raised against targets presented in their native or near-native conformation. This is critical because antibodies generated against improperly folded or non-native targets may fail to recognize the receptor as it exists on the cell surface in vivo, ultimately limiting therapeutic relevance. These systems can also be used for antibody screening, enabling the identification of binders with appropriate specificity and affinity under biologically meaningful conditions.

Finally, cell-based systems are essential for functional assays, where downstream biological activity, not just binding, is evaluated. This downstream evaluation is especially important because binding alone does not guarantee therapeutic efficacy; antibodies must modulate relevant signaling pathways, block ligand interactions, trigger internalization, or activate effector functions in a way that produces the desired biological outcome.

Common Challenges in Cell Line and Cell-Based Assay Development

Despite their importance, cell line development and cell-based assays often pose challenges that can complicate discovery programs.

One common issue is uncontrolled or non-physiological target expression: Overexpression can lead to artificial binding or non-relevant functional differences between antibody candidates. In functional assays, excessive surface density can lead to steric hindrance, resulting in misleading potency or efficacy readouts.

Primary cells can add biological and translational relevance to antibody development programs and validate results from engineered cell lines. However, their use is often limited by procurement challenges, including restricted availability, donor variability, ethical and consent requirements, and complex logistics. Short culture lifespan and lot-to-lot inconsistency can further compromise assay reproducibility, making primary cells difficult to scale and highlighting the value of robust, well-controlled cell line-based systems for most discovery workflows.

Additional challenges include limited flexibility, where a single cell line is forced to support incompatible applications. These problems can hinder lead selection and undermine confidence in downstream decisions.

Solving These Challenges Through Smarter Cell Line Design

Many of these issues can be addressed by treating cell line development and cell-based assays as strategic design decisions rather than technical checkboxes.

Assessing target expression and using high, medium, or low target expression for the right application is central to this approach. High expression levels are well-suited for immunization, medium expression supports discriminating screening assays, and low to medium expression is often optimal for functional assays that reflect human physiology. Flow cytometry data illustrating mean fold increases in expression across engineered cell populations provides a clear visual demonstration of how expression can be tuned from low to very high, supporting different discovery objectives.

Equally important is deploying a custom approach for your specific target. For instance, certain discovery programs have precise expression window requirements, such as generating cell lines expressing 5,000-10,000 copies of a target per cell. Achieving this level of control requires methodological flexibility for cell engineering, depending on the target biology and assay needs. The ability to isolate defined populations using cell sorting and single-cell cloning can help ensure consistency, stability, and reproducibility.

How Eurofins Discovery Can Help

Eurofins Discovery supports antibody discovery programs by engineering fit-for-purpose cell lines and cell-based assays aligned to your specific antibody development goals. Our deep expertise in controlling target expression through cell sorting, flexible development methodologies, and advanced sorting capabilities enables discovery teams to generate biologically relevant data earlier and with greater confidence (Figure 1). We can also manage the sourcing of primary cells to ensure clinically relevant and reproducible data.

Figure 1. Cell Sorting for Target Gene Expression.

Figure 1. Cell Sorting for Target Gene Expression. Enriching a stable cell line allows the generation of a more uniform population that expresses your target gene of interest (GOI). Eurofins Discovery uses a single cell sorter capable of detecting 3 colors, allowing us to enrich for the amount of protein of interest expressed on the cell surface.

Ultimately, successful antibody discovery depends on making the right decisions early. Thoughtfully designed cell-based assays and cell lines reduce uncertainty, reveal true biological behavior, and help teams advance the most promising candidates with confidence, setting a stronger foundation for antibody development success.

Contact us to find out how our specialized cell line development and cell-based assay capabilities can advance your antibody development.

How to Establish Cell-Based Assays for Effective Antibody Development

Cell Lines Across the Antibody Discovery Workflow

Common Challenges in Cell Line and Cell-Based Assay Development

Solving These Challenges Through Smarter Cell Line Design

How Eurofins Discovery Can Help

Read all our Biotherapeutics Blogs